We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

63 hedge funds and large institutions have $50.2M invested in Outlook Therapeutics in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 14

66% more capital invested

Capital invested by funds: $30.3M → $50.2M (+$19.9M)

29% more funds holding

Funds holding: 49 → 63 (+14)

0.19% more ownership

Funds ownership: 0.39% → 0.58% (+0.19%)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

Holders
63
Holders Change
+14
Holders Change %
+28.57%
% of All Funds
1.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
11
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.3M
2
State Street
State Street
Massachusetts
+$3.11M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.8M
4
Northern Trust
Northern Trust
Illinois
+$1.64M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.09M

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$1.87M
2
Two Sigma Investments
Two Sigma Investments
New York
-$820K
3
Millennium Management
Millennium Management
New York
-$450K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$373K
5
ECM
ExodusPoint Capital Management
New York
-$319K
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$90K +$83.5K +1,801 New
JP Morgan Chase
27
JP Morgan Chase
New York
$84K +$78K +1,681 New
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$75K +$69.9K +1,507 New
Invesco
29
Invesco
Georgia
$58K +$54.4K +1,173 New
Creative Planning
30
Creative Planning
Kansas
$57K -$1.53K -33 -3%
William Blair & Company
31
William Blair & Company
Illinois
$57K – – –
ProShare Advisors
32
ProShare Advisors
Maryland
$57K +$52.7K +1,136 New
SO
33
STRS Ohio
Ohio
$50K +$47.1K +1,015 New
Barclays
34
Barclays
United Kingdom
$42K +$17.7K +382 +81%
AllianceBernstein
35
AllianceBernstein
Tennessee
$42K +$39.4K +850 New
AB
36
Amalgamated Bank
New York
$41K +$38.4K +827 New
Victory Capital Management
37
Victory Capital Management
Texas
$36K -$1.02K -22 -3%
VF
38
Virtu Financial
New York
$35K -$7.47K -161 -19%
Principal Financial Group
39
Principal Financial Group
Iowa
$35K +$32.5K +700 New
OC
40
Oppenheimer & Co
New York
$34K +$1.16K +25 +4%
MFGP
41
Marshall Financial Group (Pennsylvania)
Pennsylvania
$30K – – –
Squarepoint
42
Squarepoint
New York
$28K -$15.5K -334 -37%
RIA
43
Realta Investment Advisors
Delaware
$27K -$2.32K -50 -8%
XT
44
XTX Topco
Cayman Islands
$27K +$25.2K +544 New
Goldman Sachs
45
Goldman Sachs
New York
$26K -$176K -3,785 -88%
CB
46
CNB Bank
Pennsylvania
$25K – – –
TW
47
TrinityPoint Wealth
Connecticut
$25K +$23.2K +500 New
Legal & General Group
48
Legal & General Group
United Kingdom
$23K +$21.5K +463 New
AIP
49
Ameritas Investment Partners
Nebraska
$17K +$15.9K +343 New
ASN
50
Advisory Services Network
Georgia
$15K +$14.1K +303 New
1
2
3 4

OTLK Hedge Fund Activity: Q2 2021 in Review

63 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2021, worth a combined $50.2M — up 66% from $30.3M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new OTLK positions and 14 closed out — a net gain of 14 holders — while 11 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $9.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $1.87M sold.

  • 63 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2021, up from 49 in Q1 2021.
  • Funds reported $50.2M of Outlook Therapeutics stock for Q2 2021, up 66% quarter-over-quarter.
  • 28 funds opened new Outlook Therapeutics positions in Q2 2021 and 14 closed out, a net change of +14 holders.
  • The largest Outlook Therapeutics buyer in Q2 2021 was BlackRock, an estimated $9.3M added.
  • The largest Outlook Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $1.87M sold.

Based on aggregated 13F filings for Q2 2021.